Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II - Results from the 8-Week Dose-Escalation PeriodThomas Doeven, Andreas Glenthøj, Richard van Wijk et al.|Blood|2024Cited by 2